WALTHAM, Mass. & MAASTRICHT, The Netherlands--(BUSINESS WIRE)--BG Medicine, Inc. (BG Medicine) and ACS Biomarker B.V. (ACS Biomarker) today announced that they have entered into an agreement pursuant to which BG Medicine obtained rights to develop and commercialize a novel clinical diagnostic test for acute atherothrombosis based on a biomarker discovered by the Cardiovascular Research Institute Maastricht (CARIM). Under the terms of the agreement, ACS Biomarker has granted BG Medicine exclusive, worldwide commercial rights to pursue the development, validation, regulatory approval and commercialization of diagnostic tests based on the biomarker discovered by CARIM, in exchange for milestone payments, royalties based on net sales and sublicensing income of any products commercialized under the license.
